Autonomic dysreflexia

Summary

Autonomic dysreflexia (MONDO:0043975) is a disease and 20 clinical trials. Top therapeutic interventions include midodrine, pyridostigmine, and fesoterodine. A subtype of autonomic nervous system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 20

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	autonomic dysreflexia
Mondo ID	MONDO:0043975
MeSH	D020211
ICD-10-CM	G90.4
ICD-11	1401282234
SNOMED CT	129618003
UMLS	C0238015
MedGen	66758
Is cancer (heuristic)	no

Also known as: autonomic dysreflexia · autonomic Dysreflexia, spinal · autonomic Dysreflexias · autonomic Dysreflexias, spinal · autonomic hyperreflexia · autonomic Hyperreflexias · Dysreflexia, autonomic · Dysreflexia, spinal autonomic · Dysreflexias, autonomic · Dysreflexias, spinal autonomic · hyperreflexia, autonomic · hyperreflexias, autonomic · spinal autonomic Dysreflexia · spinal autonomic Dysreflexias

Disease family

This is a subtype of autonomic nervous system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autonomic nervous system disorder › autonomic dysreflexia

Related subtypes (12): idiopathic peripheral autonomic neuropathy, autonomic neuropathy, autonomic nervous system neoplasm, Frey syndrome, harlequin syndrome, chronic hiccup, pure autonomic failure, baroreflex failure, dysautonomia, sympathetic nervous system disorder, parasympathetic nervous system disorder, central hypoventilation syndrome, congenital, 1, with or without Hirschsprung disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Fesoterodine.

Clinical trials & evidence

Clinical trials

Clinical trials: 20.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	15
PHASE2	3
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02298660	PHASE4	COMPLETED	Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI
NCT02919917	PHASE2/PHASE3	COMPLETED	Treatment of Post-SCI Hypotension
NCT05635851	PHASE2	NOT_YET_RECRUITING	NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI
NCT02676154	PHASE2	COMPLETED	Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)
NCT02893553	PHASE2	COMPLETED	The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
NCT04493372	Not specified	RECRUITING	Deciphering Preserved Autonomic Function After Spinal Cord Injury
NCT05351827	Not specified	RECRUITING	Mild Intermittent Hypoxia: A Prophylactic for Autonomic Dysfunction in Individuals With Spinal Cord Injuries
NCT05369520	Not specified	RECRUITING	Non-invasive Spinal Cord Stimulation for Recovery of Autonomic Function After Spinal Cord Injury
NCT06211491	Not specified	RECRUITING	Autonomic Dysreflexia in Spinal Cord Injuries: UDS Filling Speed Impact
NCT07012135	Not specified	RECRUITING	Deciphering Preserved Autonomic Function After Multiple Sclerosis
NCT07456722	Not specified	NOT_YET_RECRUITING	Cardiac Morphology and Function in Individuals With Autonomic Dysreflexia
NCT07504055	Not specified	RECRUITING	Non-invasive Spinal Cord Stimulation and Blood Pressure Regulation After Spinal Cord Injury
NCT00175682	Not specified	COMPLETED	Prazosin Vibrostimulation Autonomic Dysreflexia and Spinal Cord Injury Study
NCT02006433	Not specified	COMPLETED	Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury With Deep Brain Stimulation
NCT03307161	Not specified	COMPLETED	Osteopathic Manual Treatment Parkinson’s Disease and Truncal Dystonia
NCT03924388	Not specified	UNKNOWN	Spinal Cord Stimulation and Autonomic Response in People With SCI.
NCT04193709	Not specified	COMPLETED	Recovery of Bladder and Sexual Function After Human Spinal Cord Injury
NCT04858178	Not specified	COMPLETED	Transcutaneous Spinal Cord Neuromodulation to Normalize Autonomic Phenotypes
NCT05024487	Not specified	UNKNOWN	Prevention of Complications Due to Autonomic Dysreflexia in SCI Individuals
NCT05380661	Not specified	COMPLETED	Heart Rate Variability and Anxiety During Urinary Bladder Catheterization

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MIDODRINE	4	6
PYRIDOSTIGMINE	4	2
FESOTERODINE	4	1
MIRABEGRON	4	1
PRAZOSIN HYDROCHLORIDE	4	1
(R)-MIDODRINE	0	2